Prazosin for ETOH or Cocaine Craving

• Status: Terminated
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This double-blind placebo controlled crossover pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduces craving for their drug of choice in cocaine-dependent and alcohol-dependent veterans. Both the study medication period and the placebo period are each 4 weeks in duration.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Adrenergic Antagonists; Cocaine; Prazosin

Criteria

Inclusion Criteria:

• Age 18-70 years

• Current DSM-IV diagnosis of alcohol dependence or cocaine dependence with no use in last 30 days

• Capacity to provide informed consent

• Actively enrolled in chemical dependency treatment at VA Puget Sound English fluency

Exclusion Criteria:

• Evidence of significant abuse of opiates, PCP, sedatives or anxiolytics

• Suicidal ideation

• DSM IV diagnosis of bipolar mood disorder, schizophrenia or schizoaffective disorder

• Significant acute or chronic medical illness, including unstable angina, recent myocardial infarction, history of congestive heart failure, preexisting hypotension (systolic < 110), or orthostatic hypotension (systolic drop > 20mmHg after two minutes standing or any drop with dizziness), insulin-dependent diabetes mellitus; chronic renal or hepatic failure, pancreatitis, gout, M ni re's disease, benign positional vertigo, narcolepsy

• Concomitant use of alpha-1 antagonists History of prazosin-sensitivity Women who are pregnant, nursing infant(s), or of childbearing potential and not using a contraceptive method judged by the investigator to be effective

• Non-compliance with outpatient chemical dependency treatment